Austin, TX, July 15, 2025 (GLOBE NEWSWIRE) -- Vibrant Gastro, inventor of the groundbreaking Vibrant ® System, a non-pharmaceutical treatment for chronic idiopathic constipation, today announced it has been honored with a series of awards and recognitions in recent weeks including the prestigious TAG Award for MedTech , which hailed Vibrant Gastro as the “Top MedTech Innovator of 2025.”  The award, which recognizes “game-changing technologies, products, and services” that “create a new benchmark for excellence,” was presented at the MD&M East design and manufacturing expo held in New York City. Hear from Vibrant Gastro CEO Asaf Bar in the TAG Awards' Beyond the Award podcast episode , “From Taboo to Transformative: The MedTech Innovation that Is Changing Lives.”  Vibrant Gastro has also been honored by MedTech Outlook as the “Top New Innovator for Chronic Constipation in 2025” and was listed among 2025's 10 most innovative medical device companies by Inc. Magazine.  Chronic idiopathic constipation affects over one in 10 American adults — disproportionately women and people of color — and existing treatments negatively affect their quality of life. Traditional and prescription laxatives cause sudden on-set diarrhea — uncomfortable, uncontrollable and unpredictable. In fact, 60% of patients say the treatments are worse than the constipation itself, and 78% of physicians dislike existing treatments.  The Vibrant® System works differently, using a vibrating capsule to restore the colon's natural rhythm and put patients back in control. Studies show that Vibrant® has a low rate of side effects, with just 1.2% of patients reporting diarrhea compared to 16% who are prescribed linaclotide, which is the current standard of care. [1] Since Vibrant® is not a drug, there are no drug-to-drug interactions, unlike traditional and prescription medications.  An analysis of safety data from five developmental studies and a final pivotal phase III study that led to FDA clearance of the Vibrant® System, published recently by Dr. Bryan Curtin from Mercy Medical Center in Baltimore, found patients to be highly satisfied with Vibrant®. [3] Patients experienced so few side effects that none of the 800 participants in the studies stopped taking the prescription treatment.  An additional study found Vibrant® is both less expensive and more adhered to than linaclotide. [4] The study, published in Advances in Therapy , found 55% more patients stay on Vibrant® for a full year compared to those prescribed linaclotide. Costly adverse events also dramatically decreased with Vibrant® compared to linaclotide such as ER visits for severe diarrhea, which averaged $2,418 per visit, and inpatient hospital stays that averaged $15,080.  A post hoc analysis of Vibrant®'s Phase 3 trial, published last year by Cleveland Clinic, demonstrated significant benefits for patients with severe chronic idiopathic constipation. In this group, 93% improved, and 19% reached at least three complete spontaneous bowel movements per week—suggesting substantial relief from their condition.  “Vibrant® offers real, lasting help to the tens of millions of Americans whose lives have been ruined by chronic idiopathic constipation,” said Vibrant Gastro CEO, Asaf Bar. “Our latest honor by the TAG Awards builds on recognition from TIME's Best Inventions and Fast Company's World Changing Ideas. All are evidence that Vibrant® is the answer that patients and physicians have sought for so long.”  Vibrant Gastro is pleased to announce the Vibrant® System is now covered by a range of leading health insurance plans, reaching an estimated 42 million lives across the United States. To learn more, visit VibrantGastro.com  About Vibrant ®  Over 1 in 10 American adults — disproportionately women and people of color — struggle with chronic constipation, and existing treatments ruin their quality of life with 60% saying the treatments, which cause diarrhea, are worse than the constipation. Vibrant® is an FDA-cleared drug-free treatment that uses a vibrating capsule to restore the colon's natural rhythm and put you back in control. Clinical results show Vibrant® provides one, two and sometimes three additional complete spontaneous bowel movements weekly, even in severe adult patients, with just 1.2% of patients reporting diarrhea. Since Vibrant® is not a drug, there are no interactions with other drugs, unlike traditional and prescription laxatives. Learn more at vibrantgastro.com  Attachments  Vibrant Gastro  asaf.b@vibrantgastro.com  Legal Disclaimer:  EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Trio of Prestigious Awards Honors Drug-Free Chronic Constipation Treatment: Vibrant®

Newton, Massachusetts, UNITED STATES
BOSTON, Nov.  28, 2023  (GLOBE NEWSWIRE) -- TIME has honored Vibrant, the groundbreaking drug-free treatment for chronic constipation by Vibrant Gastro, as part of its list of 2023’s Best Inventions. Up to one in five American adults — disproportionately women and people of color — struggle to have bowel movements, and existing treatments ruin their quality of life. Traditional and prescription laxatives cause sudden on-set diarrhea — uncomfortable, uncontrollable and unpredictable. In fact, 60% of patients say the treatments are worse than the constipation itself. “That’s not the case with the … Vibrant System — a prescription, non-pharmacological capsule programmed to vibrate eight to 10 hours after ingestion, when it reaches the large intestine,” writes TIME’s Katie MacBride. “The vibrations stimulate nerve cells involved in peristalsis, the process that pushes food through the digestive system. When the capsule’s work is done, it passes through the patient and is flushed away.”
Vibrant restores the colon’s natural rhythm and puts you back in control with consistent bowel movements at predictable times. Studies show that Vibrant has a low rate of side effects, with just 1.2% of patients reporting diarrhea. Since Vibrant is not a drug, there are no interactions with other drugs, unlike traditional and prescription laxatives. “Being honored among TIME’s Best Inventions is further validation that Vibrant offers a real answer for the tens of millions of Americans whose lives are upended by chronic constipation,” said Vibrant Gastro CEO John Schellhorn. “The strong interest we’ve seen since Vibrant’s clearance by the FDA demonstrates how patients and physicians have long sought a real solution for a life-altering problem.”
About Vibrant
Up to 1 in 5 American adults — disproportionately women and people of color — struggle with chronic constipation and existing treatments ruin their quality of life with 60% saying the treatments, which cause diarrhea, are worse than the constipation. Vibrant is a new FDA-cleared drug-free treatment that uses a vibrating capsule to restore the colon’s natural rhythm and put you back in control. Clinical results show Vibrant provides one, two and sometimes three additional complete spontaneous bowel movements weekly, even in severe adult patients, with just 1.2% of patients reporting diarrhea. Since Vibrant’s not a drug, there are no interactions with other drugs, unlike traditional and prescription laxatives. Learn more at vibrantgastro.com . Gallery of images available here
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4adeb8c0-4a0a-44ea-9157-d20e79c5f696

TIME Honors Vibrant’s Chronic Constipation Treatment Among 2023’s Best Inventions

A+
Washington [US], June 18 (ANI): A study led by Laureate Institute for Brain Research researchers has made significant progress in understanding the mysterious gut-brain connection, a complex relationship that has long baffled scientists due to the difficulty of accessing the body’s interior. The study was published in the peer-reviewed scientific journal ‘Nature Communications.’
The researchers were able to successfully have participants swallow a minimally invasive vibrating capsule in order to measure neural responses during gastrointestinal stimulation, providing a novel approach to studying this intricate connection. The capsule was designed by Vibrant Ltd. Healthy adult male and female volunteers ranging in age from 18 to 40 took part in the study. According to the researchers, the volunteers detected stimulation of the vibrating capsule under two conditions: normal and enhanced. The improved stimulation condition resulted in improved perceptual accuracy, faster stimulation detection, and reduced variability in reaction time, indicating that this method has the potential to be studied in various clinical populations. This is a significant breakthrough because it shows that this novel approach to studying gut feelings is viable. The researchers also discovered the “gastric evoked potential,” a late neural response induced by capsule stimulation in specific brain areas. The amplitude of these neural responses increased with stimulation intensity and was significantly related to perceptual accuracy. This finding opens up new possibilities for measuring and understanding the neural processes that govern the gut-brain connection. “We were able to localize most of the capsule stimulations to the gastroduodenal segments of the digestive tract using abdominal X-ray imaging,” said Dr Sahib Khalsa, a psychiatrist and neuroscientist at LIBR, and senior author of the study. “This finding is crucial as it provides a more precise understanding of where these gut-brain interactions are originating.”
“The potential clinical implications for the results of this study are substantial,” said Dr Khalsa. “The vibrating capsule method could transform the clinical approach to disorders of gut-brain interaction, including eating disorders and certain gastrointestinal disorders such as irritable bowel syndrome (IBS) or functional dyspepsia.”
Dr. Khalsa continued. “This would provide a much-needed tool for assessing gut sensation in these conditions and could lead to more personalized and effective treatment strategies. It also opens up the possibility of identifying perceptual or biological mediators of successful treatment, which could serve as predictive markers for future therapeutic interventions.” (ANI)
This report is auto-generated from ANI news service. ThePrint holds no responsibility for its content. Subscribe to our channels on YouTube & Telegram
Support Our Journalism
India needs fair, non-hyphenated and questioning journalism, packed with on-ground reporting. ThePrint – with exceptional reporters, columnists and editors – is doing just that. Sustaining this needs support from wonderful readers like you. Whether you live in India or overseas, you can take a paid subscription by clicking here .

Researchers get new insights into human gut-brain connection

Tulsa, Okla. – A pioneering study conducted by researchers at the Laureate Institute for Brain Research (LIBR) in Tulsa, Okla., has made significant strides in understanding the elusive gut-brain connection, a complex relationship that has long puzzled scientists due to the difficulty of accessing the body’s interior. The study, “Parieto-occipital ERP indicators of gut mechanosensation in humans,” appears in the peer-reviewed scientific journal Nature Communications. The research team successfully had participants swallow a minimally invasive vibrating capsule to measure neural responses during gastrointestinal stimulation, providing a novel approach to study this intricate connection. The capsule was developed by Vibrant Ltd. Participants in the study included healthy adult male and female volunteers ages 18-40. The researchers found that the volunteers were able to sense the stimulation of the vibrating capsule under two conditions: normal and enhanced. The enhanced stimulation condition led to improved perceptual accuracy, faster detection of the stimulation, and reduced variability in reaction time, indicating potential for studying this method in different clinical populations. This is a significant breakthrough as it demonstrates the feasibility of this novel approach to studying gut feelings. The researchers also discovered the “gastric evoked potential,” a late neural response in certain areas of the brain specifically induced by capsule stimulation. These neural responses increased in amplitude depending on the intensity of the stimulation and were significantly correlated with perceptual accuracy. This discovery provides a new way to measure and understand the neural processes governing the gut-brain connection. “We were able to localize most of the capsule stimulations to the gastroduodenal segments of the digestive tract using abdominal X-ray imaging,” said Dr. Sahib Khalsa, a psychiatrist and neuroscientist at LIBR, and senior author of the study. “This finding is crucial as it provides a more precise understanding of where these gut-brain interactions are originating.”
“The potential clinical implications for the results of this study are substantial,” said Dr. Khalsa. “The vibrating capsule method could transform the clinical approach to disorders of gut-brain interaction, including eating disorders and certain gastrointestinal disorders such as irritable bowel syndrome (IBS) or functional dyspepsia.”
Dr. Khalsa continued. “This would provide a much-needed tool for assessing gut sensation in these conditions and could lead to more personalized and effective treatment strategies. It also opens up the possibility of identifying perceptual or biological mediators of successful treatment, which could serve as predictive markers for future therapeutic interventions.”
The research team was led by senior author Sahib Khalsa, MD, PhD, Director of Clinical Operations at the Laureate Institute for Brain Research and Associate Professor in the Oxley College of Health Sciences at The University of Tulsa. Co-first authors on the study were Ahmad Mayeli, PhD and Obada Al Zoubi, PhD who were a PhD student and postdoctoral scholar, respectively, from LIBR at the start of the project. The research was supported by the National Institute of Mental Health and The William K. Warren Foundation and was conducted at LIBR between September 2019 and February 2022. # # #
CONTACT: For more information about the project, contact Sahib Khalsa, MD, PhD, at Laureate Institute for Brain Research at [email protected] . ABOUT LAUREATE INSTITUTE FOR BRAIN RESEARCH (LIBR) Launched in 2009, the Laureate Institute for Brain Research (laureateinstitute.org) is home to a multidisciplinary team of scientists and clinical research staff who apply neuroimaging, genetic, pharmacological, neuropsychological and psychotherapeutic methods to investigate the neurobiology and treatment of psychiatric disorders. LIBR’s creation was supported by The William K. Warren Foundation for the purpose of conducting studies aimed at developing more effective treatments and/or prevention strategies for these disorders. The studies are led by scientists from diverse backgrounds, including psychiatry, psychology, physics, cognitive neuroscience, developmental neuroscience, population neuroscience and genetics, molecular and cellular neurobiology, and computer science. Journal

Groundbreaking study reveals new insights into human gut-brain connection

Laureate Institute for Brain Research
Tulsa, Okla. – A pioneering study conducted by researchers at the Laureate Institute for Brain Research (LIBR) in Tulsa, Okla., has made significant strides in understanding the elusive gut-brain connection, a complex relationship that has long puzzled scientists due to the difficulty of accessing the body's interior. The study, “Parieto-occipital ERP indicators of gut mechanosensation in humans,” appears in the peer-reviewed scientific journal Nature Communications. The research team successfully had participants swallow a minimally invasive vibrating capsule to measure neural responses during gastrointestinal stimulation, providing a novel approach to study this intricate connection. The capsule was developed by Vibrant Ltd. Participants in the study included healthy adult male and female volunteers ages 18-40. The researchers found that the volunteers were able to sense the stimulation of the vibrating capsule under two conditions: normal and enhanced. The enhanced stimulation condition led to improved perceptual accuracy, faster detection of the stimulation, and reduced variability in reaction time, indicating potential for studying this method in different clinical populations. This is a significant breakthrough as it demonstrates the feasibility of this novel approach to studying gut feelings. The researchers also discovered the “gastric evoked potential,” a late neural response in certain areas of the brain specifically induced by capsule stimulation. These neural responses increased in amplitude depending on the intensity of the stimulation and were significantly correlated with perceptual accuracy. This discovery provides a new way to measure and understand the neural processes governing the gut-brain connection. “We were able to localize most of the capsule stimulations to the gastroduodenal segments of the digestive tract using abdominal X-ray imaging,” said Dr. Sahib Khalsa, a psychiatrist and neuroscientist at LIBR, and senior author of the study. “This finding is crucial as it provides a more precise understanding of where these gut-brain interactions are originating.”
“The potential clinical implications for the results of this study are substantial,” said Dr. Khalsa. “The vibrating capsule method could transform the clinical approach to disorders of gut-brain interaction, including eating disorders and certain gastrointestinal disorders such as irritable bowel syndrome (IBS) or functional dyspepsia.”
Dr. Khalsa continued. “This would provide a much-needed tool for assessing gut sensation in these conditions and could lead to more personalized and effective treatment strategies. It also opens up the possibility of identifying perceptual or biological mediators of successful treatment, which could serve as predictive markers for future therapeutic interventions.”
The research team was led by senior author Sahib Khalsa, MD, PhD, Director of Clinical Operations at the Laureate Institute for Brain Research and Associate Professor in the Oxley College of Health Sciences at The University of Tulsa. Co-first authors on the study were Ahmad Mayeli, PhD and Obada Al Zoubi, PhD who were a PhD student and postdoctoral scholar, respectively, from LIBR at the start of the project. The research was supported by the National Institute of Mental Health and The William K. Warren Foundation and was conducted at LIBR between September 2019 and February 2022. # # #
CONTACT: For more information about the project, contact Sahib Khalsa, MD, PhD, at Laureate Institute for Brain Research at skhalsa@laureateinstitute.org. ABOUT LAUREATE INSTITUTE FOR BRAIN RESEARCH (LIBR) Launched in 2009, the Laureate Institute for Brain Research (laureateinstitute.org) is home to a multidisciplinary team of scientists and clinical research staff who apply neuroimaging, genetic, pharmacological, neuropsychological and psychotherapeutic methods to investigate the neurobiology and treatment of psychiatric disorders. LIBR’s creation was supported by The William K. Warren Foundation for the purpose of conducting studies aimed at developing more effective treatments and/or prevention strategies for these disorders. The studies are led by scientists from diverse backgrounds, including psychiatry, psychology, physics, cognitive neuroscience, developmental neuroscience, population neuroscience and genetics, molecular and cellular neurobiology, and computer science. Journal

Shunra

ESI Group

FriCSo

These startups aim to provide health treatments, diagnosis tools, and products that do not require a prescription or connection with a health professional to enhance personal wellbeing. This includes supplements, women's health maintenance, OTC medicines, and more.

Beauty & Personal Care

Other Investors

Series E

Vibrant is a company focused on providing a drug-free treatment for chronic idiopathic constipation in the healthcare sector. Their main offering is a capsule that utilizes micro-vibration technology to stimulate bowel movements. The company also offers a companion smartphone app for patients to monitor their progress. It was founded in 2010 and is based in Newton, Massachusetts.

Date	Round	Amount	Investors	Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.	Revenue	Sources
3/26/2021	Series E	$7.5M	Unorthodox Ventures	$XXM	0 FY undefined	5
8/1/2018	Seed VC		Subscribe to see more	$XXM	0 FY undefined	0
	Other Investors		Subscribe to see more	$XXM	0 FY undefined	10

Date	3/26/2021	8/1/2018
Round	Series E	Seed VC	Other Investors
Amount	$7.5M
Investors	Unorthodox Ventures	Subscribe to see more	Subscribe to see more
Valuation	$XXM	$XXM	$XXM
Revenue	0 FY undefined	0 FY undefined	0 FY undefined
Sources	5	0	10

First funding	Last Funding	Investor	Rounds	Type	Location
3/26/2021	3/26/2021	Unorthodox Ventures	2 Other Investors, Series E (2021)	Venture Capital
00/00/0000	00/00/0000	Gefen Capital	Subscribe to see more	Venture Capital	Israel
		Precede Technologies	Subscribe to see more	Angel Investor (Group)	California
		Sequoia Capital Israel	Subscribe to see more	Venture Capital	Israel

First funding	3/26/2021	00/00/0000
Last Funding	3/26/2021	00/00/0000
Investor	Unorthodox Ventures	Gefen Capital	Precede Technologies	Sequoia Capital Israel
Rounds	2 Other Investors, Series E (2021)	Subscribe to see more	Subscribe to see more	Subscribe to see more
Board Seats
Type	Venture Capital	Venture Capital	Angel Investor (Group)	Venture Capital
Location		Israel	California	Israel

How VCs Use CB Insights

Professional Services

Platform Overview

Vibrant

Total Raised

Investors Count

Funding, Valuation & Revenue

Vibrant Investors